InvestorsHub Logo
Followers 33
Posts 2859
Boards Moderated 1
Alias Born 10/24/2015

Re: None

Friday, 08/06/2021 12:45:26 PM

Friday, August 06, 2021 12:45:26 PM

Post# of 1610
Late preclinical programs in IND-enabling studies include a novel IL-2 analog (IOV-3001) as well as a genetically modified TIL (IOV-4001). IOV-4001 leverages TALEN tech licensed from CLLS to knock out the PD-1 gene in TIL.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IOVA News